Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
The human epidermal growth factor receptor (EGFR) is an important therapeutic target in patients with metastatic colorectal cancer and anti-EGFR antibodies cetuximab and panitumumab have been approved for the treatment of such patients. Despite these advances, the duration of response in some patien...
Main Authors: | Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan Michael Seddon, Helmout Modjtahedi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24609222/?tool=EBI |
Similar Items
-
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with <i>RAS</i> Wild Type Metastatic Colorectal Cancer
by: Said A. Khelwatty, et al.
Published: (2021-02-01) -
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
by: Aryan Stanley, et al.
Published: (2017-06-01) -
Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
by: Daniel Tong, et al.
Published: (2021-06-01) -
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
by: Gustavo A. Arias-Pinilla, et al.
Published: (2021-04-01) -
The duke /
by: 375070 Foley, Gaelen
Published: (2000)